CA
ACOR

Corrado Advisors’s Acorda Therapeutics ACOR Stock Holding History

Corrado Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-88
Closed -$221K – 117
2016
Q3 		$221K Buy
+88
New +$263K 0.14% 89

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Corrado Advisors's ACOR Position: Q4 2016 in Review

Corrado Advisors sold out of Acorda Therapeutics (ACOR) in Q4 2016, closing a stake of 88 shares — an estimated $221K sold.

Corrado Advisors first reported a position in ACOR in Q3 2016 and held it in 1 quarter. The position peaked at $221K in Q3 2016. 175 funds tracked by Wall St. Rank hold ACOR as of Q4 2016.

  • Corrado Advisors reported no remaining Acorda Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Corrado Advisors sold 88 Acorda Therapeutics shares in Q4 2016, an estimated $221K.
  • Corrado Advisors first reported a position in Acorda Therapeutics in Q3 2016 and held it in 1 quarter.
  • Corrado Advisors's Acorda Therapeutics position peaked at $221K in Q3 2016.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2016.

Based on Corrado Advisors's 13F filing for Q4 2016, filed 10 Jan 2017.